Phase 1 study of CNTX-6970 in patients with inflammatory pain
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2017
At a glance
- Drugs CNTX 6970 (Primary)
- Indications Inflammatory pain
- Focus Adverse reactions
- Sponsors Centrexion Therapeutics
- 26 Sep 2017 According to a Centrexion Therapeutics media release, data will be presented at the 11th Annual Pain and Migraine Therapeutics Summit 2017.
- 18 Jul 2017 Status changed from recruiting to completed according to a Centrexion Therapeutics media release.
- 01 Apr 2016 New trial record